We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Entera Bio Ltd. (ENTX) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
Entera Bio Ltd. (ENTX - Free Report) closed at $0.90 in the latest trading session, marking a -1% move from the prior day. This change lagged the S&P 500's 0.25% gain on the day. Meanwhile, the Dow gained 0.08%, and the Nasdaq, a tech-heavy index, added 7.26%.
Heading into today, shares of the company had gained 35.86% over the past month, outpacing the Medical sector's loss of 0.75% and the S&P 500's gain of 5.73% in that time.
Investors will be hoping for strength from Entera Bio Ltd. as it approaches its next earnings release. In that report, analysts expect Entera Bio Ltd. to post earnings of -$0.12 per share. This would mark a year-over-year decline of 157.14%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $0.1 million, down 41.18% from the year-ago period.
Investors should also note any recent changes to analyst estimates for Entera Bio Ltd.These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Entera Bio Ltd. is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 83, which puts it in the top 33% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ENTX in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Entera Bio Ltd. (ENTX) Stock Sinks As Market Gains: What You Should Know
Entera Bio Ltd. (ENTX - Free Report) closed at $0.90 in the latest trading session, marking a -1% move from the prior day. This change lagged the S&P 500's 0.25% gain on the day. Meanwhile, the Dow gained 0.08%, and the Nasdaq, a tech-heavy index, added 7.26%.
Heading into today, shares of the company had gained 35.86% over the past month, outpacing the Medical sector's loss of 0.75% and the S&P 500's gain of 5.73% in that time.
Investors will be hoping for strength from Entera Bio Ltd. as it approaches its next earnings release. In that report, analysts expect Entera Bio Ltd. to post earnings of -$0.12 per share. This would mark a year-over-year decline of 157.14%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $0.1 million, down 41.18% from the year-ago period.
Investors should also note any recent changes to analyst estimates for Entera Bio Ltd.These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Entera Bio Ltd. is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 83, which puts it in the top 33% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ENTX in the coming trading sessions, be sure to utilize Zacks.com.